Pleural mesothelioma (PM) is mainly caused by asbestos exposure and characterized by poor prognosis and limited therapeutic options. A recent research study led by Karin Schelch and Michael Grusch from MedUni Vienna identified ...
Oct 11, 2023
0
2
A combination immunotherapy treatment of nivolumab plus ipilimumab was associated with no improvement in survival for advanced cancers other than melanoma, when compared to nivolumab alone, according to a recent Northwestern ...
Sep 22, 2023
0
59
A model developed by the International Association for the Study of Lung Cancer in 2009 to help better stage mesothelioma cases performed well, according to an independent analysis presented at The International Association ...
Sep 12, 2023
0
0
Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to platinum and pemetrexed ...
Sep 11, 2023
0
5
Identifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International ...
Sep 9, 2023
0
16
Peter Szlosarek, Professor of Medical Oncology at Queen Mary's Barts Cancer Institute, presented his team's results from the ATOMIC-Meso clinical trial in partnership with Polaris Pharmaceuticals, Inc., at the American Association ...
Apr 18, 2023
0
15
Treatment outcomes for patients with malignant pleural mesothelioma, a rare cancer commonly known as mesothelioma, are often affected by social determinants of health, and overall survival rates could be improved by addressing ...
Mar 23, 2023
0
39
Rice University and Baylor College of Medicine researchers have shown they can eradicate advanced-stage mesothelioma tumors in mice in just a few days with a treatment combining Rice's cytokine "drug factory" implants and ...
Aug 22, 2022
0
177
The PrE0505 phase 2 clinical trial results are published in the November 8 issue of Nature Medicine. The study evaluated the addition of durvalumab immunotherapy to standard chemotherapy in patients with previously untreated, ...
Nov 8, 2021
0
1
The monoclonal antibodies nivolumab and ipilimumab have already undergone several early benefit assessments in various oncological indications. Since April 2021, the drug combination has also been approved for first-line ...
Oct 4, 2021
0
0
